Quiz: Epidemiology and Treatment of Advanced, Metastatic Skin Cancer

Question 1

Answer

C.3–5 months

Metastatic skin cancer tumors in the brain are a dire diagnosis, with a median survival time ranging from 3–5 months.

Question 2

Answer

B.58%

ERK pathway inhibition causes tumor shrinkage of metastatic skin cancer tumors harboring activating BRAF mutations. Of 76 patients in the study, 44 (58%) experienced tumor responses on dabrafenib plus trametinib, with a median time to progression of 5.6 months (95% CI, 5.3–7.4 months).

Question 3

Answer

A.Vemurafenib, encorafenib or vemurafenib

Encorafenib with or without binimetinib demonstrated better efficacy than vemurafenib, and encorafenib plus binimetinib "appears to have an improved tolerability profile" compared with encorafenib or vemurafenib, the study authors reported.

Question 4

Answer

C.Superior; superior

Obesity appears to be associated with improved PFS and OS compared with patients with normal BMI, particularly among men treated with targeted therapy and immunotherapy, according to a study published in the Lancet Oncology in February.

Question 5

Answer

D.Air Force

Active duty and military veteran populations experience elevated skin cancer risk, with the highest rates occurring in the US Air Force, according to a recent review of published studies.